CytoKi Pharma is a biotechnology company focused on developing novel medicines for diseases with a significant unmet medical need with focus on serious diseases caused by epithelial injury. Our lead program is based on an engineered long-acting IL-22 protein licensed from a major pharma company.
Interleukin-22 is a key player in protecting and repairing tissues upon an injury. It is a unique cytokine in that it is released from immune cells but does not target immune cells. A correctly functioning immune system is essential in keeping us healthy in the multitude of challenges our organism encounters.